Table 2 Main results of the meta-analysis
N.of studies | N. of patients | HR(95%CIs) | Heterogeneity test | |||
|---|---|---|---|---|---|---|
Q | I-squared | P-value | ||||
OS | ||||||
Overall | 31 | 6394 | 1.60(1.36,1.89) | 204.53 | 85.30% | <0.001 |
Stage | ||||||
I–IIIA | 6 | 1138 | 2.18(1.70,2.80) | 5.99 | 16.60% | 0.307 |
IIIB–IV | 9 | 1290 | 1.47(1.02,2.11) | 68.04 | 88.20% | <0.001 |
Mix(I–IV) | 16 | 3966 | 1.52(1.24,1.88) | 116.06 | 87.10% | <0.001 |
Surgical intervention | ||||||
Surgery | 10 | 1997 | 1.94(1.42,2.67) | 85.90 | 89.50% | <0.001 |
Non-surgery | 8 | 1114 | 1.24(0.79,1.95) | 70.54 | 90.10% | <0.001 |
Chemotherapy | ||||||
EGFR-TKI | 6 | 665 | 1.83(1.31,2.58) | 14.84 | 66.30% | 0.011 |
Platinum-based | 8 | 1218 | 1.53(1.18,1.99) | 24.67 | 71.60% | 0.001 |
Ethnicity | ||||||
Asian | 17 | 4096 | 1.62(1.25,2.09) | 160.26 | 90.00% | <0.001 |
Caucasian | 13 | 2210 | 1.60(1.31,1.95) | 36.48 | 67.10% | <0.001 |
Sample size | ||||||
Small | 20 | 2246 | 1.66(1.35,2.03) | 68.62 | 72.30% | <0.001 |
Large | 11 | 4148 | 1.53(1.16,2.00) | 130.45 | 92.30% | <0.001 |
Study design | ||||||
Prospective | 11 | 1542 | 1.58(1.27,1.96) | 30.18 | 66.90% | 0.001 |
Retrospective | 18 | 4478 | 1.75(1.38,2.22) | 155.27 | 89.10% | <0.001 |
PFS | ||||||
Overall | 7 | 1061 | 1.41(1.19,1.69) | 24.54 | 75.60% | <0.001 |
